Neogenomics Stock Beneish M Score

NEO Stock  USD 13.42  0.11  0.81%   
This module uses fundamental data of NeoGenomics to approximate the value of its Beneish M Score. NeoGenomics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out NeoGenomics Piotroski F Score and NeoGenomics Altman Z Score analysis.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
  
At this time, NeoGenomics' Interest Debt Per Share is very stable compared to the past year. As of the 23rd of April 2024, Long Term Debt To Capitalization is likely to grow to 0.47, while Short and Long Term Debt is likely to drop about 3.9 M. At this time, NeoGenomics' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 23rd of April 2024, Average Inventory is likely to grow to about 516.6 K, while Price To Sales Ratio is likely to drop 3.26.
At this time, it appears that NeoGenomics is an unlikely manipulator. The earnings manipulation may begin if NeoGenomics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by NeoGenomics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of NeoGenomics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.87
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

1.0

Focus
Asset Quality

1.0

Focus
Expense Coverage

1.0

Focus
Gross Margin Strengs

0.68

Focus
Accruals Factor

1.0

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

1.05

Focus
Financial Leverage Condition

1.0

Focus

NeoGenomics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if NeoGenomics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables137.8 M131.2 M
Sufficiently Up
Slightly volatile
Total Revenue621.2 M591.6 M
Sufficiently Up
Slightly volatile
Total Assets1.8 B1.7 B
Sufficiently Up
Slightly volatile
Total Current Assets626.7 M596.8 M
Sufficiently Up
Slightly volatile
Non Current Assets Total1.1 B1.1 B
Sufficiently Up
Slightly volatile
Property Plant Equipment123.8 M117.9 M
Sufficiently Up
Slightly volatile
Depreciation And Amortization76.2 M72.6 M
Sufficiently Up
Slightly volatile
Selling General Administrative255.3 M243.1 M
Sufficiently Up
Slightly volatile
Total Current Liabilities101.1 M96.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total675.6 M643.4 M
Sufficiently Up
Slightly volatile
Short Term Debt7.7 M5.6 M
Significantly Up
Very volatile
Long Term Debt565.1 M538.2 M
Sufficiently Up
Slightly volatile
Gross Profit Margin0.280.4134
Way Down
Slightly volatile

NeoGenomics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between NeoGenomics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards NeoGenomics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find NeoGenomics' degree of accounting gimmicks and manipulations.

About NeoGenomics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Other Operating Expenses

722.71 Million

At this time, NeoGenomics' Other Operating Expenses is very stable compared to the past year.

NeoGenomics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as NeoGenomics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables94.2M106.8M112.1M119.7M131.2M137.8M
Total Revenue408.8M444.4M484.3M509.7M591.6M621.2M
Total Assets709.5M988.3M1.9B1.7B1.7B1.8B
Total Current Assets290.7M448.7M681.5M605.3M596.8M626.7M
Net Debt(40.1M)(10.5M)296.0M347.7M269.2M282.7M
Short Term Debt13.8M7.8M8.0M6.7M5.6M7.7M
Long Term Debt91.8M168.1M532.5M535.3M538.2M565.1M
Operating Income8.4M(2.1M)(10.0M)(153.1M)(107.7M)(102.3M)
Investments(19.6M)(93.3M)(133.8M)517K76.7M80.5M

About NeoGenomics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NeoGenomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Piotroski F Score and NeoGenomics Altman Z Score analysis.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
Note that the NeoGenomics information on this page should be used as a complementary analysis to other NeoGenomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for NeoGenomics Stock analysis

When running NeoGenomics' price analysis, check to measure NeoGenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoGenomics is operating at the current time. Most of NeoGenomics' value examination focuses on studying past and present price action to predict the probability of NeoGenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoGenomics' price. Additionally, you may evaluate how the addition of NeoGenomics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is NeoGenomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.70)
Revenue Per Share
4.714
Quarterly Revenue Growth
0.121
Return On Assets
(0.04)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.